Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Tenofovir Alafenamide 25 mg in Healthy Adults (Fed)
NCT06592300Phase 1Completed
- Sponsor
- Humanis
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Humanis. Primary endpoints: Maximum plasma concentration at 6 hours and Area under the plasma concentration curve from administration to last observed concentration at 6 hours. Started Jul 2024; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06592300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592300.